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Group III metabotropic glutamate receptors (mGluRs) undergo post-translational modiﬁcation by SUMO
in in vitro assays but the SUMOylation of full-length mGluRs in mammalian cells has not been reported.
Herewe investigated SUMOylation ofmGluR7 inHEK293 cells andprimary cortical neurons in an attempt
to conﬁrm SUMOylation and deﬁne physiological effects on mGluR7 function. Using a recombinant bac-
terial expression assay we validated in vitro SUMOylation of the C-terminal domain of mGluR7 by both
SUMO-1andSUMO-2andshowthat a single lysine residue (K889) inmGluR7 is required for SUMOylation.
However, using a range of approaches, we were unable to detect SUMOylation of full-length mGluR7 inUMOylation
GluR7
bc9
biquitin
ost-translational modiﬁcation
PCR
GluR7
either heterologous cells or neurons. Further, we observed no differences in receptor stability or surface
expression between wild-type and a non-SUMOylatable point mutant mGluR7. Thus, our results ques-
tion whether mGluR7, and by implication other group III mGluRs, are physiologically relevant neuronal
SUMO substrates.
© 2011 Elsevier Ireland Ltd. Open access under CC BY license.etabotropic glutamate receptor
etabotropic glutamate receptors (mGluRs) are G protein-coupled
eceptors (GPCRs) that regulate synaptic function.Group IIImGluRs
mGluR4, mGluR6, mGluR7 and mGluR8) are mostly presynaptic
nd act as autoreceptors to inhibit glutamate release via sev-
ral pathways. With the exception of mGluR6, which is largely
estricted to postsynaptic sites of retinal rod bipolar cells, group III
GluRs are expressedwidely throughout the brain at both the RNA
nd the protein levels and, interestingly, they are present at both
lutamatergic and GABAergic terminals (reviewed in Ref. [14]).
SUMO(SmallUbiquitin-likeMOdiﬁer)proteinsare∼11kDapro-
eins that can be covalently conjugated to lysine residues in target
roteins, altering the biochemical and/or functional properties of
he modiﬁed protein. Three SUMO paralogues (SUMO-1–3) have
een identiﬁed in vertebrate brain. SUMO-1 was ﬁrst reported as
protein conjugated to the nuclear pore complex protein RanGAP
12] and several hundred targets of SUMOylation have since been
dentiﬁed. SUMO-2 and SUMO-3 differ by just three N-terminal
mino acids but they share only∼50% sequence identity to SUMO-1
5]. Proteins are SUMOylated via an enzymatic cascade analogous
o ubiquitination. Brieﬂy, SUMO proteins are ﬁrst activated by the
ction of an E1 ‘activating’ enzyme, which passes the activated
UMO to the E2 ‘conjugating’ enzyme. The only E2 enzyme in the
∗ Corresponding author. Tel.: +44 117 9546 449; fax: +44 117 9291 687.
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Open access under CC BY license.SUMOylation pathway is Ubc9, which usually, but not always, in
conjunction with an E3 ‘ligase’ enzyme, catalyses the SUMO conju-
gation to the substrate (reviewed in Ref. [21]).
Yeast two-hybrid assays using the intracellular C-terminus of
the group III receptor mGluR8 isolated PIAS1 (Protein Inhibitor of
Activated STAT) [20], an E3 component of the SUMOylation path-
way. Those workers went on to show that PIAS1 interacted with
each of the group III mGluRs in vitro and that the C-terminus of
mGluR8 could be SUMOylated inHEK293 cellswhen expressed as a
GST-fusion protein [20].More recently, we demonstrated that each
of the group III mGluRs was SUMOylated in a recombinant bacte-
rial in vitro SUMOylation assay [23]. Subsequent yeast two-hybrid
assays using mGluR8b as bait isolated Ubc9 as well as the SUMO
E3 enzymes PIAS1 and PIAS3 as interacting proteins [19]. Inter-
estingly, that study also identiﬁed Ubc12 as a potential mGluR8
interactor [19]. Ubc12 is a conjugating enzyme speciﬁc to another
ubiquitin-like protein, Nedd8 (for review see [16]), suggesting that
neddylation, in addition to SUMOylation and ubiquitination may
play a role in the regulation of neurotransmitter receptors at the
synapse.
Despite these data demonstrating SUMOylation of C-terminal
domain constructs, SUMO modiﬁcation of full-length group III
mGluRs has not been reported and the functional consequences
of this modiﬁcation, should it occur, are unclear. We therefore
sought to identify the site of modiﬁcation in mGluR7, con-
struct a full-length SUMOylation deﬁcient mutant and analyse the
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onsequences. We conﬁrm robust SUMOylation of the C-terminus
f mGluR7 in vitro and show that this is prevented by mutation of
he lysine residue K889. However, we were unable to detect SUMO
odiﬁcation of the full-length receptor in either heterologous cells
r neurons. Further, no differences in receptor expression levels,
ignalling or surface expression were detected between wild-type
GluR7 and the non-SUMOylatable mutant. Thus, our data ques-
ion whether mGluR7, and by implication other group III mGluRs
re genuine SUMO substrates in mammalian cells.
Mutagenesis: mGluR7(K889R) was made using Quikchange II
L site-directed mutagenesis (Stratagene) using either pRK5-SEP-
GluR7 (for mammalian expression) or pGEX-mGluR7-ct (for
acterial expression) as a template. The presence of the mutation
as conﬁrmed by DNA sequencing.
Cell culture: HEK293 cells and cortical neurons were cultured
s described previously [2]. Brieﬂy, cortical neurons were plated
n Neurobasal media (Gibco), containing 5% horse serum, B27 sup-
lement, glutamax and penicillin/streptomycin at a density of 0.5
illion per 35mm dish. After 24h the media were changed and
eurons were used at ∼14DIV.
mGluR7 solubilisation: Cultured neurons or HEK293 cells were
ysed in RIPA buffer (10mM Tris–HCl pH 7.5, 150mM NaCl, 1%
riton X-100, 1% sodium deoxycholate, 0.1% SDS, 20mM NEM,
ontaining completemammalianprotease inhibitors (Roche)), son-
cated for 10 s andproteins solubilisedby rotationon awheel at 4 ◦C
or 1h. Lysates were then centrifuged at 16,000× g for 20min and
he supernatant collected.
SDS-PAGE and Western blotting: Proteins were separated using
–12% acrylamide gels and blotted onto Immobilonmembranes for
estern blotting with the antibodies indicated. Blots were quanti-
ed by densitometry of at least three separate experiments using
IH ImageJ. Themean± SEMvales arepresented and,where appro-
riate signiﬁcance was determined using Student’s t tests.
Surface biotinylation: Surface protein was isolated as previously
escribed [8]. Brieﬂy, HEK293 cells expressing SEP-mGluR7 or
on-SUMOylatablemutantwere labelledwithNHS-Sulfo-SS-Biotin
0.15mg/ml in PBS; Pierce) for 20min at 4 ◦C, washed three times
n PBS and neutralised with PBS containing 50mM NH4Cl. After
ﬁnal PBS wash, cells were lysed and solubilised. Fifty micro-
iters of washed streptavidin agarose (Sigma) was incubated with
0–100g cleared lysate. Protein was eluted from the beads with
0–100l 2xSDS-PAGE loading buffer and Western blotted.Immunoprecipitation: 200–400g of solubilised cleared neu-
onal lysate was incubated with 2–4g rabbit polyclonal mGluR7
ntibody (Upstate) at 4 ◦C for 1–2h. Fifty microlitres of Protein
beads were then added to each IP and allowed to incubate for
ig. 1. mGluR7 can be modiﬁed by both SUMO-1 and SUMO-2 at lysine 889 in vitro: Th
ysine (K889R) were tested for SUMO modiﬁcation in the bacterial SUMOylation assay w
or GST (top panels) or GST-mGluR7 puriﬁed and probed for SUMO-1 or SUMO-2 (bottom
nly SUMOylatable lysine in the C-terminus of mGluR7, and this lysine can be modiﬁed bnce Letters 491 (2011) 181–186
another hour. After extensive washing with lysis buffer, protein
was then eluted from the beads by addition of 50l 2xSDS-PAGE
loading buffer and Western blotted.
GFP-trap: Washed GFP-trap A beads (Chromotek) were mixed
with solubilised protein for 1h at 4 ◦C before extensive washing
and elution of the bound protein with 2xSDS-PAGE loading buffer
and Western blotting.
ERK assays: HEK293 cells were transfected with 1g mGluR7
DNA and 24h later complete DMEM (Dulbecco’s modiﬁed Eagle
medium (Gibco) containing 10% fetal calf serum, 2mM l-glutamine
and 100U/ml penicillin/streptomycin) was removed and cells
washed twice and incubated in unsupplemented DMEM to reduce
basal serum-stimulated ERK activation for 12–16h. DMEM was
then replaced with either vehicle or mGluR agonist. After stim-
ulation, DMEM was removed and cells lysed directly in 500l
SDS-PAGE loading buffer. Lysates were sonicated brieﬂy to reduce
viscosity before analysis via Western blotting.
Imaging: Live cell imaging was performed as previously
described [7]. 13DIV cortical neurons were transfected with SEP-
mGluR7using lipofectamine2000. Live cell imagingwasperformed
5 days after transfection using an inverted confocal microscope
(Axiovert 200M, Zeiss, Germany). Transfected (green) cells were
selected and confocal sensitivity adjusted to allow both increases
and decreases in ﬂuorescence caused by pH changes to stay
within the dynamic range. Fluorescencewas excited at 488nm and
detected at 505nm. Images were sampled every 30 s.
mGluR7 contains a SUMOylation consensus motif in the intra-
cellular C-termini that can be SUMOylated by SUMO-1 in bacterial
SUMOylation assays [23]. Here we show that mGluR7 can also
be SUMOylated in vitro by SUMO-2. To determine the site of
SUMO modiﬁcation we constructed a mutant of GST-ct-mGluR7
in which the positively charged consensus lysine residue (K889)
was changed to a positively charged non-SUMOylatable arginine
residue. As shown in Fig. 1, a single ∼50kDa higher molecular
weight species was observed with SUMO-1 (A) or SUMO-2 (B)
in the wild-type GST-ct-mGluR7 but not the K889 mutant. The
lowerpanel shows that this higherbandwas speciﬁcally recognised
by anti-SUMO antibodies. Thus, mutation of the consensus lysine
residue abolished modiﬁcation by both SUMO-1 and SUMO-2.
To monitor the surface expression, lateral diffusion and endo-
cytosis of mGluR7 we constructed full-length mGluR7(WT) and
mGluR7(K889R) tagged with super-ecliptic pHluorin (SEP) at the
extracellular N-terminal. SEP is a variant of GFP that is recog-
nised by our anti-GFP antibody but which has been mutated to
render the ﬂuorescent signal sensitive to pH [1]. Consistent with
a previous report [15], expression and surface trafﬁcking of SEP-
e C-termini of mGluR7 wild-type or a mutant lacking the SUMOylation consensus
ith either SUMO-1 (A) or SUMO-2 (B). Crude bacterial lysates were either probed
panels). SUMO-modiﬁed mGluR7 is indicated by an arrow. K889 appears to be the
y both SUMO-1 and SUMO-2.
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Fig. 2. Expression and surface trafﬁcking of a wild-type and non-SUMOylatable SEP-mGluR7 in HEK293 cells: (A) SEP-mGluR7 was transfected into HEK293 cells. Thirty-six
hours post-transfection, surface proteins were labelled with biotin, the cells lysed and biotinylated surface proteins were isolated on streptavidin beads and subjected to
Western blotting alongside total lysate for GFP (SEP). (B) SEP-mGluR7was transfected into 13DIV primary cortical neurons and imaged for SEP expression 5 days later (upper
panel). SEP ﬂuorescence was reduced with a transient exposure to pH 6.0 buffer consistent with the majority of the signal arising from surface expressed SEP-mGluR7.
Application of ammonium chloride, which collapses pH gradients across the plasma membrane and transiently equilibrates intracellular compartments to the extracellular
pH increased ﬂuorescence showing the total SEP signal (pH 7.4) orminimum signal (pH 6). The ﬂuorescence of the region boxed in the upper panel is shown graphically in the
lower panel. (C) SEP-mGluR7 is functional in HEK293 cells, as assayed for its ability to activate the ERK pathway. Data are the mean± SEM, **p<0.01 (Student’s t-test, n=3).
(D) SEP-mGluR7 WT or K889R was transfected into HEK293 cells. Thirty-six hours post-transfection cells were lysed in SDS-PAGE loading buffer and subjected to Western
blotting for GFP (mGluR7) or -actin to ensure equal loading. (E) SEP-tagged mGluR7 WT or K889R was transfected into HEK293 cells. Thirty-six hours post-transfection,
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estern blotting alongside total lysate for either GFP (mGluR7) or-actin to conﬁrm
s shown graphically normalized to the wild-type. The blots are representative of th
ere not signiﬁcant in Student’s t-test.GluR7 was conﬁrmed in HEK293 cells by surface biotinylation
nd Western blotting (Fig. 2A), and via live cell imaging in trans-
ected cortical neurons (Fig. 2B). Further, ERK assays in transfected
EK293 assays indicate that SEP-mGluR7 is functionally active
Fig. 2C).ubatedwith streptavidin beads to isolate labelled surface proteins and subjected to
peciﬁcity of surface labelling. The proportion of total mGluR7(K889R) at the surface
parate experiments and the mean± SEM are shown in the bar graphs; differencesTo determine whether expression levels of mGluR7 were
affected by mutation of the SUMOylatable lysine (K889), HEK293
cells were transfected with the WT or non-SUMOylatable
mGluR7(K889R) mutant and total lysates were Western blotted
for mGluR7 (Fig. 3A). Total levels of mGluR7 were unaffected by
184 K.A. Wilkinson, J.M. Henley / Neuroscie
Fig. 3. ERK activation downstream of a non-SUMOylatable mGluR7 is identical to
wild-typemGluR7. (A) SEP-mGluR7WTorK889Rwas transfected intoHEK293 cells.
Twenty-four hours post-transfection, cells were serum-starved for at least 6h to
reduce basal ERK signalling. Cells were then stimulated with the Group III mGluR
agonist L-AP4 for the times indicated, lysed in SDS-PAGE loading buffer and sub-
jected to Western blotting for GFP (mGluR7) or phospho-ERK. (B) ERK activation
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higher order oligomers and they are difﬁcult to immunoprecipi-t the times indicated is shown normalized to the wild-type. Data are shown as
ean± SEM for three separate experiments. There is no signiﬁcant difference in the
uration or extent of ERK activation between WT and non-SUMOylatable mGluR7.
he K889R mutation. To assess surface expression we used mem-
rane impermeant Sulfo-NHS-Biotin, streptavidin pulldowns and
ubsequent Western blotting of surface versus total fractions. For
uantiﬁcation, the level of surface expressed mGluR7 was nor-
alized to the total mGluR7 for each experimental condition. The
ar graph (Fig. 3B) shows the proportion of surface expressed
GluR7(K889R) normalized to the proportion observed for wild-
ype mGluR7. Similar levels of surface expression were observed
or both the mGluR7(WT) and the SUMOylation-deﬁcient mutant
GluR7(K889R).
Group III mGluRs signal in part via activation of the ERK
AP kinase pathway [6]. To determine whether the extent and
uration of ERK activation differed between a wild-type and non-
UMOylatable mGluR7(K889R), HEK293 cells were transfected
ith either SEP-mGluR7(WT) or SEP-mGluR7(K889R), stimulated
ith the group III mGluR-speciﬁc agonist L-AP4 (800M) for
arious times and lysates blotted for phospho-ERK. Both the mag-
itude of the initial response and the length of the response
desensitization) were indistinguishable between a wild-type and
on-SUMOylatable mGluR7 (Fig. 4).
The lack of identiﬁable affect in preventing mGluR7 SUMOy-
ation led us to query whether mGluR7 is indeed a bona ﬁde
ubstrate for SUMOylation. To address this directly HEK293 cells
ere transfectedwith plasmids encoding SEP-mGluR7(WT) or SEP-
GluR7(K889R) together with FLAG-Ubc9 and YFP-SUMO-1 and
otal cell lysates were analysed by Western blotting. We did not
etect any SUMOylation of mGluR7, despite clear SUMOylation
f the previously reported SUMO substrate GluR6 in the same
ssay [10] (Fig. 4A,and B). To increase the sensitivity of the assay,
ells were lysed and SEP-mGluR7 immunoprecipitated on GFP-
rap beads and blotted for FLAG-SUMO. Again, although robustnce Letters 491 (2011) 181–186
SUMOylation of GluR6 was detected no SUMOylation of mGluR7
was observed (Fig. 4C and D). One possible explanation might be
thatHEK293 cells are not an appropriate system to analyse SUMOy-
lation of mGluR7, for example because of insufﬁcient levels of an
E3. Therefore, we performed immunoprecipitation experiments
from cultured cortical neurons. 14DIV cortical cultures were lysed,
mGluR7 immunoprecipitated andWestern blotted for SUMO-1. As
shown in Fig. 4E and F, mGluR7 was present in the cell lysates and
was depleted in the bead-supernatant indicating immunoprecip-
itation of mGluR7 under these conditions, but no SUMOylated
mGluR7 was detected.
Previous results, including from our own lab, have shown
that group III mGluRs can bind components of the SUMOylation
machinery and that in recombinant systems the soluble C-terminal
domains are robustly SUMOylated [20,23]. These data suggested
that SUMOylationof group IIImGluRsmight play roles in regulating
presynaptic release and in mGluR-dependent forms of metaplas-
ticity. Here we show that lysine 889 in mGluR7 is SUMOylated by
SUMO-1 and SUMO-2 in vitro and we engineered a SUMO deﬁcient
mGluR7(K889R) mutant to deﬁne the roles of SUMOylation in the
full-length receptor. Expression of wild-type or non-SUMOylatable
mGluR7 in HEK293 cells, which lack endogenous mGluR7, allowed
direct comparison between the properties of the recombinant
receptors. Surprisingly, mGluR7(WT) and mGluR7(K889R) were
indistinguishable in total receptor expression, surface trafﬁcking
and ERK activation making it unlikely that this modiﬁcation regu-
lates receptor stability, mGluR7 trafﬁcking or signalling.
Another study has reported that mGluR7 is capable of interact-
ing with Ubc9 in a yeast two-hybrid screen [19]. Yeast two-hybrid
assays are undoubtedly a useful tool for the identiﬁcation of
potential protein interactions but they can fail to detect known
interactions and often identify potential interacting partners that
donot genuinely interact in vivodue to their structure, regulationor
cellular localisation in mammalian cells [13]. Further, while inter-
action with Ubc9 is generally a good indication of potential SUMO
modiﬁcation, it is unclear whether this is necessarily the case for
membrane proteins. Nuclear proteins that interact with Ubc9 have
a high probability of being targets for SUMOylation due to the high
levelsof SUMOandUbc9 in thenucleus. Indeed, it hasbeen reported
that a SUMOylation consensus motif and a nuclear localisation sig-
nal are all that is required for SUMOylation of a substrate protein to
occur [17]. Levels of Ubc9 and SUMO at the cell periphery are likely
to be lower, so in the case of plasma membrane proteins, identi-
fying an in vitro interaction with Ubc9 may not necessarily mean
that the protein of interest is a genuine SUMO substrate. For simi-
lar reasons our identiﬁcation of robust SUMOylation of each of the
group III mGlu receptors in the bacterial SUMOylation assay [23]
must also be treated with caution.
Although extensively used, HEK293 cells might not accurately
represent the situation in neurons. For example, it is possible that
neuron-speciﬁc factors could regulate the stability, surface traf-
ﬁcking or G protein-coupling and that interactions with these
factors are required to deﬁne a functional consequence of mGluR7
SUMOylation. This is exempliﬁed by our observation mGluR7 does
not undergo agonist-induced endocytosis in HEK293 cells (data
not shown). Similarly, it has been reported that mGluR7 does
not undergo agonist-induced endocytosis in HeLa cells [9]. Thus,
the rapid and robust activity-dependent endocytosis of mGluR7
reported in neurons could be mediated by a neuron-speciﬁc
mechanism. In addition, it is well established that mGluRs are
relatively insoluble, they have a tendency to run as dimers ortate and immunoblot [3]. Despite the fact that in in vitro assays
we observe robust SUMOylation, we have been unable to ver-
ify mGluR7 SUMOylation in either heterologous cells or neurons
although in the same experiments we did observe SUMOylation
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Fig. 4. SUMOylation of mGluR7was not detected in HEK293 cells or neurons. (A) SEP-mGluR7was co-transfected into HEK293 cells in the presence or absence of FLAG-Ubc9
and YFP-SUMO-1. Cells were lysed in SDS-PAGE loading buffer and subjected to Western blotting for mGluR7. The two bands represent monomers and dimers of mGluR7,
but a band representing a SUMO-modiﬁed form ofmGluR7was not detected. (B) As (A), except cells were transfected with amyc-tagged form of the kainate receptor subunit
GluR6 or the non-SUMOylatable K886R mutant. Note the presence of a SUMOylated higher molecular weight form of GluR6 upon expression of YFP-SUMO-1 which is not
present for the K886R mutant. (C) HEK293 cells transfected with YFP-GluR6, SEP-mGluR7 or their non-SUMOylatable mutants (denoted as KR) along with FLAG-Ubc9 and
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f GluR6 as previously reported [10]. Therefore, while we cannot
eﬁnitively rule out the possibility that mGluR7 is SUMOylated,
ur results appear to questionwhethermGluR7 is a physiologically
elevant SUMO substrate.
Several papers have discussed the potential role of SUMOyla-
ion in group III mGluR function. For example, it has been proposed
hat SUMOylation of mGluR7 may explain how PICK1 can still
e partially immunoprecipitated with mGluR7 from transgenic
ice lacking the mGluR7 PDZ ligand [24]. Further, reviews of
UMOylation have cited group III mGluRs as examples of surface-
xpressed SUMO substrates (for example [4,11,18,22]). While our
ata support previous observations that the C-terminus of mGluR7
s SUMOylated, our lack of conﬁrmatory results using the full-
ength receptor suggest these reports may be premature and, in
he worst case scenario, imply that group III mGluR SUMOylation
ay be restricted to recombinant systems and not occur at native
eceptors under physiologically relevant conditions. Thus, further
ork will be required to conﬁrm the SUMOylation status of the
roup III mGluRs and deﬁne the roles, if any, SUMOylation plays on
hese receptors.Western blotted for FLAG. (D) Inputs and equivalent amounts of bead supernatant
. (E) 14DIV cortical neurons were lysed, mGluR7 immunoprecipitated and blotted
nt amount of input to determine pulldown of mGluR7 was successful. (F) Inputs
Acknowledgements
We are grateful to the MRC, the Wellcome Trust and the Euro-
pean Research Council for ﬁnancial support. We thank Yasuko
Nakamura for expert confocal supervision, Philip Rubin and Patrick
Tidball for technical assistance and Dr. Ken Pelkey (NIH) for sup-
plying a version of the SEP-mGluR7 plasmid.
References
[1] M.C. Ashby, S.R. Maier, A. Nishimune, J.M. Henley, Lateral diffusion drives con-
stitutive exchange of AMPA receptors at dendritic spines and is regulated by
spine morphology, J. Neurosci. 26 (2006) 7046–7055.
[2] T. Bouschet, S.Martin, J.M.Henley, Regulationof calcium-sensing-receptor traf-
ﬁcking and cell-surface expression by GPCRs and RAMPs, Trends Pharmacol Sci
29 (2008) 633–639.[3] K.K. Dev, S. Nakanishi, J.M. Henley, Regulation of mglu(7) receptors by proteins
that interactwith the intracellularC-terminus, TrendsPharmacol. Sci. 22 (2001)
355–361.
[4] R. Geiss-Friedlander, F. Melchior, Concepts in sumoylation: a decade on, Nat.
Rev. Mol. Cell Biol. 8 (2007) 947–956.
[5] R.T. Hay, SUMO: a history of modiﬁcation, Mol. Cell 18 (2005) 1–12.
1 roscie
[
[
[
[
[
[
[
[
[
[
[
[
[
[86 K.A. Wilkinson, J.M. Henley / Neu
[6] L. Iacovelli, L. Capobianco, M. Iula, V. Di Giorgi Gerevini, A. Picascia, J. Blahos,
D. Melchiorri, F. Nicoletti, A. De Blasi, Regulation ofmGlu4metabotropic gluta-
mate receptor signaling by type-2 G-protein coupled receptor kinase (GRK2),
Mol. Pharmacol. 65 (2004) 1103–1110.
[7] F. Jaskolski, B. Mayo-Martin, D. Jane, J.M. Henley, Dynamin-dependent mem-
branedrift recruitsAMPAreceptors todendritic spines, J. Biol. Chem.284 (2009)
12491–12503.
[8] S. Kantamneni, D. Holman, K.A. Wilkinson, A. Nishimune, J.M. Henley, GISP
increases neurotransmitter receptor stability by down-regulating ESCRT-
mediated lysosomal degradation, Neurosci. Lett. 452 (2009) 106–110.
[9] G. Lavezzari, K.W. Roche, Constitutive endocytosis of the metabotropic gluta-
mate receptormGluR7 is clathrin-independent, Neuropharmacology 52 (2007)
100–107.
10] S. Martin, A. Nishimune, J.R. Mellor, J.M. Henley, SUMOylation regu-
lates kainate-receptor-mediated synaptic transmission, Nature 447 (2007)
321–325.
11] S. Martin, K.A. Wilkinson, A. Nishimune, J.M. Henley, Emerging extranuclear
roles of protein SUMOylation in neuronal function and dysfunction, Nat. Rev.
Neurosci. 8 (2007) 948–959.
12] M.J. Matunis, E. Coutavas, G. Blobel, A novel ubiquitin-like modiﬁcation
modulates the partitioning of the Ran-GTPase-activating protein RanGAP1
between the cytosol and the nuclear pore complex, J. Cell Biol. 135 (1996)
1457–1470.
13] A. Nishimune, S.R. Nash, S. Nakanishi, J.M. Henley, Detection of protein–protein
interactions in the nervous system using the two-hybrid system, Trends Neu-
rosci. 19 (1996) 261–266.
14] C.M. Niswender, P.J. Conn, Metabotropic glutamate receptors: physiology,
pharmacology, and disease, Annu. Rev. Pharmacol. Toxicol. 50 (2010) 295–322.
[nce Letters 491 (2011) 181–186
15] K.A. Pelkey, X. Yuan, G. Lavezzari, K.W. Roche, C.J. McBain, mGluR7 under-
goes rapid internalization in response to activation by the allosteric agonist
AMN082, Neuropharmacology 52 (2007) 108–117.
16] G. Rabut, M. Peter, Function and regulation of protein neddylation. ‘Protein
modiﬁcations: beyond the usual suspects’ review series, EMBO Rep. 9 (2008)
969–976.
17] M.S. Rodriguez, C. Dargemont, R.T. Hay, SUMO-1 conjugation in vivo requires
both a consensus modiﬁcation motif and nuclear targeting, J. Biol. Chem. 276
(2001) 12654–12659.
18] A. Scheschonka, Z. Tang, H. Betz, Sumoylation in neurons: nuclear and synaptic
roles? Trends Neurosci. 30 (2007) 85–91.
19] A. Seebahn, M. Rose, R. Enz, RanBPM is expressed in synaptic layers of the
mammalian retina and binds to metabotropic glutamate receptors, FEBS Lett.
582 (2008) 2453–2457.
20] Z. Tang, O. El Far, H. Betz, A. Scheschonka, Pias1 interaction and sumoylation of
metabotropic glutamate receptor 8, J. Biol. Chem. 280 (2005) 38153–38159.
21] K.A. Wilkinson, J.M. Henley, Mechanisms, regulation and consequences of pro-
tein SUMOylation, Biochem. J. 428 (2010) 133–145.
22] K.A.Wilkinson, Y. Nakamura, J.M. Henley, Targets and consequences of protein
SUMOylation in neurons, Brain Res. Rev. 64 (2010) 195–212.
23] K.A. Wilkinson, A. Nishimune, J.M. Henley, Analysis of SUMO-1 modiﬁcation
of neuronal proteins containing consensus SUMOylationmotifs, Neurosci. Lett.
436 (2008) 239–244.
24] C.S. Zhang, F. Bertaso, V. Eulenburg, M. Lerner-Natoli, G.A. Herin, L. Bauer, J.
Bockaert, L. Fagni, H. Betz, A. Scheschonka, Knock-in mice lacking the PDZ-
ligand motif of mGluR7a show impaired PKC-dependent autoinhibition of
glutamate release, spatial working memory deﬁcits, and increased suscepti-
bility to pentylenetetrazol, J. Neurosci. 28 (2008) 8604–8614.
